Josh Enomoto

Josh Enomoto

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Can Niu Technologies Keep Charging Ahead After Its Massive Rally?

With e-mobility being all the rage these days, NIU stock has benefited tremendously but caution may be warranted now.

7 Renewable Energy Stocks to Help the Environment and Your Wallet

President-elect Joe Biden doesn’t just represent a political rethink but rather, an environmental one. Therefore, these renewable energy stocks should be on your radar.

Senate Control Could Determine Where Palantir Stock Heads Next

After roughly tripling in value over the past few weeks, Palantir stock has become a hot commodity. But where it goes from here depends on the political environment.

9 Cryptos Set to Explode in 2021

With uncertainty pinging in the equities sector, the crypto market has enjoyed a robust resurgence. Here’s a visual breakdown of the best virtual currencies to consider.

It’s Best to Wait Until January for Electrameccanica Vehicles

SOLO stock suddenly turned from a risky idea to a hot commodity on Wall Street. Still, you should note some challenges ahead.

The Science Behind Kensington Capital Could Electrify Your Portfolio

Solid-state batteries (SSBs) represent the future of electric vehicles, bolstering the narrative for KCAC stock. However, investors should know what makes SSBs distinct -- and the challenges that lie ahead.

9 Video Game Stocks to Buy for Next-Gen Gains

Video games offered a respite from the shock of the novel coronavirus. So, logically, lightning could strike twice for this viable sector.

Windows of Opportunity Are Tightening for Sorrento Therapeutics

Thanks to Sorrento Therapeutics’ all-out pivot to address the Covid-19 pandemic, SRNE stock initially became one of the most popular investments. But as both the vaccine and treatment race tighten, the risks multiply.

Slack Just Got a Lifeline from Salesforce Buyout Talks

Finally, investors were justified in holding onto WORK stock. However, it's still a question what the proposed deal will mean for CRM stock?

Hyliion Stock Could Be Science’s Version of Affidavits

Hyliion stock seems like a compelling idea on paper, but it’s in the finer details where the narrative gets incredibly complicated.